4-morpholino-2-[3-(2-propenyloxycarbonylamino)benzylamino]-6-(5-propyl-1,3-oxazol-2-ylthiomethyl)pyridine | 196498-62-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 偶氮苯
• 英文名称: 4-morpholino-2-[3-(2-propenyloxycarbonylamino)benzylamino]-6-(5-propyl-1,3-oxazol-2-ylthiomethyl)pyridine
• 英文别名: prop-2-enyl N-[3-[[[4-morpholin-4-yl-6-[(5-propyl-1,3-oxazol-2-yl)sulfanylmethyl]pyridin-2-yl]amino]methyl]phenyl]carbamate
• CAS: 196498-62-1
• 化学式: C₂₇H₃₃N₅O₄S
• 分子量: 523.656
• InChiKey: AYRRFUWNHNXUES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  37
• 可旋转键数：
  13
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  127
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• AMINOPYRIDINE DERIVATIVES
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP0889034A1

  公开（公告）日：1999-01-07

  The present invention relates to a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, and a treating agent for hyperphagia, obesity or diabetes, which comprises such a compound or salt as an active ingredient: [wherein Ar1 is an aryl group or an aromatic heterocyclic group, which may be substituted by a group selected from the group consisting of a lower alkyl group, a lower hydroxyalkyl group, a lower alkylene group and a group represented by -NRaRb; R1 is a hydrogen atom or a lower alkyl group; each of R2 and R3 which are the same or different, is a lower alkyl group, or both of R2 and R3 are bonded to each other to form an alkylene group which may have an oxygen atom or a sulfur atom interposed, said alkylene group being a group which may be substituted by one or two lower alkyl groups; R4 is a hydrogen atom, or a lower alkyl group which may be substituted by a group selected from the group consisting of a hydroxyl group, an amino group, a carbamoyl group and a lower alkoxycarbonyl group; Ar2 is an aryl group or an aromatic heterocyclic group, which may be substituted by a group selected from the group consisting of a halogen atom, a hydroxyl group, a lower alkyl group, a lower haloalkyl group, a lower alkoxy group, a lower alkylthio group, a lower hydroxyalkyl group, a lower alkoxy-lower alkyl group, a group represented by -NRcRd and a group represented by -NRe-CO-NRfRg; W is an oxygen atom, a sulfur atom, or a group represented by -CHRj- or -NRk-].

  本发明涉及一种通式(I)代表的化合物或其药学上可接受的盐，以及一种治疗食欲亢进、肥胖或糖尿病的药物，其有效成分包括这样的化合物或盐： [其中 Ar1 是芳基或芳香杂环基，可被选自由低级烷基、低级羟烷基、低级亚烷基和 -NRaRb 所代表的基团组成的基团取代；R1 是氢原子或低级烷基；相同或不同的 R2 和 R3 中的每一个都是低级烷基，或 R2 和 R3 两者相互键合形成一个亚烷基，该亚烷基中可能有一个氧原子或一个硫原子，所述亚烷基是一个可被一个或两个低级烷基取代的基团；R4 是氢原子，或可被选自羟基、氨基、氨基甲酰基和低级烷氧基羰基的基团取代的低级烷基；Ar2 是芳基或芳香杂环基，可被选自由卤素原子、羟基、低级烷基、低级卤代 烷基、低级烷氧基、低级烷硫基、低级羟烷基、低级烷氧基-低级烷基、由 -NRcRd 表示的基团和由 -NRe-CO-NRfRg 表示的基团组成的组取代；W 是氧原子、硫原子或由 -CHRj- 或 -NRk- 代表的基团]。
• US6011039A
  申请人：——

  公开号：US6011039A

  公开（公告）日：2000-01-04